Panelists discuss how treatment decisions in multiple myeloma are guided by disease risk, patient health, and evolving ...

Teclistamab-cqyv is a T-cell-engaging bispecific antibody that targets multiple myeloma cells via the B-cell maturation ...

Medically reviewed by Archana Sharma, DO Diagnosing multiple myeloma, also referred to as myeloma, is often a complex process. While this rare blood cancer can cause many complications, it can't be ...

The FDA granted accelerated approval of linvoseltamab-gcpt for certain patients with multiple myeloma.Specifically, the ...

We diagnose multiple myeloma by doing blood, urine, bone marrow, and imaging tests. The disease can be classified as being “smoldering myeloma,” which is typically closely monitored, and “active ...

The Food and Drug Administration (FDA) has granted accelerated approval to Lynozyfic™ (linvoseltamab-gcpt) for the treatment of adult patients with ...

Like treatments for many other cancers, treatments for multiple myeloma come with a high price. The drugs are “hideously expensive,” Dr. June said, costing more than $100,000 a year.

We conducted a phase 1b–2 study of talquetamab plus teclistamab in patients with relapsed or refractory multiple myeloma. In phase 1, we investigated five dose levels in a dose-escalation study.

Association between patient demographics and smoldering multiple myeloma progression to multiple myeloma: A SEER-Medicare data analysis, Clinical Lymphoma Myeloma and Leukemia, (2025). https://doi ...

Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma. New England Journal of Medicine , 2024; DOI: 10.1056/NEJMoa2409029 Cite This Page : ...